Carey said the take-home message is “if you have a patient who’s had MS and optic neuritis, and they call your office saying, ...

https://eyewire.news/articles/first-patient-screened-in-mallinckrodt-phase-4-trial-of-h-p-acthar-gel-for-severe-noninfectious-intermediate-uveitis-posterior-uveitis ...

Significant benefits were reported in steroid-free quiescence, retinal vascular leakage, macular edema, and visual functioning No new safety signals were identified, and Priovant plans an FDA ...

The release noted that brepocitinib demonstrated consistent benefits in preventing treatment failure across key subgroups, ...

A study of 30.7 million US children revealed that pediatric uveitis incidence rose from 22 to 33 per 100,000 between 2016 and 2025.

Roivant and Priovant report brepocitinib met the primary endpoint in Phase III uveitis trials. Read the latest results and ...

<?xml encoding="utf-8" ?> Roivant Sciences Ltd. ROIV and its subsidiary Priovant Therapeutics announced positive results Wednesday from two Phase 3 trials evaluating brepocitinib for noninfectious ...

KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...

Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase ...

Oil futures are financial contracts that allow participants to buy or sell a specific quantity of oil at a predetermined price on a future date. These contracts serve as an agreement between the buyer ...